Stratipath today announced that Linköping University Hospital and Region Östergötland have chosen to implement Stratipath Breast as part of their clinical routine for early breast cancer diagnostics.
Stratipath Breast is a CE-IVD marked AI tool that provides rapid and cost-efficient prognostic risk profiling of breast cancer using routine pathology slides. With results available in less than 60 minutes, the solution significantly shortens the time from biopsy to treatment decision, empowering clinicians with timely and actionable information at the point of diagnosis.
“We are proud that Region Östergötland and Linköping University Hospital are joining the growing number of healthcare providers using Stratipath Breast,” said Fredrik Wetterhall, CEO and co-founder of Stratipath. “By making AI-driven risk profiling part of routine diagnostics, we are helping physicians make more confident treatment decisions while improving access to precision medicine.”
With healthcare systems facing increasing diagnostic workloads and pressure to deliver timely, personalized care, Stratipath Breast offers a critical alternative to expensive and time-consuming molecular assays. By using AI to analyze routine H&E-stained tissue slides, the tool helps clinicians more accurately assess the risk of relapse in patients with invasive breast cancer – particularly in ER+/HER2- cases where traditional grading falls short.
Per Wastesson, pathologist at Linköping University Hospital commented: “We are looking forward to locally evaluate the implementation of Stratipath Breast. We have high expectations for what it could bring to our clinical workflow, as well as to the broader prognostic risk assessment by the oncologists to more patients as part of routine care.”
“This implementation is an important step towards more equitable and sustainable cancer care,” said Professor Johan Hartman, Chief Medical Officer and co-founder of Stratipath. “By providing a cost-efficient and scalable solution, Stratipath Breast enables broader access to precision diagnostics, helping more patients receive the right treatment faster.”
Stratipath Breast will be fully integrated with Sectra’s digital pathology platform, already in use at Linköping University Hospital, enabling a seamless and efficient diagnostic workflow. The implementation of Stratipath Breast in Region Östergötland is supported by the Swedish Regional Cancer Center (RCC).